Publications by the researcher in collaboration with Francisco Fuentes Jiménez (31)

2024

  1. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet, Vol. 403, Núm. 10421, pp. 55-66

  3. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet

  3. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  4. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

2021

  1. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  2. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

  3. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  4. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

    The Lancet, Vol. 398, Núm. 10312, pp. 1713-1725

  5. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  6. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

    Drugs, Vol. 81, Núm. 6, pp. 685-695

  7. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: The SAFEHEART study

    Public Health Nutrition, Vol. 22, Núm. 8, pp. 1433-1443

  2. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

2018

  1. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study

    Journal of Clinical Lipidology, Vol. 12, Núm. 4, pp. 948-957